News - PreviPharma Consulting GmbH Homepage

PreviPharma today announces the start of a strategic partnership with global biotherapeutics leader CSL Behring to collaboratively develop novel plasma protein-based medicines. This new strategic partnership further strengthens the existing relationship between the parties, which have been collaborating on various projects since September 2018. Under the terms of this agreement, PreviPharma will receive set biannual funding for a period of three years, with possible extension for a further two years.

“As a company driven by its promise to patients, we are excited about our further collaboration with PreviPharma, which seeks to identify new plasma proteins for the treatment of diseases with high unmet medical need,” says Dr. Adrian Zuercher, VP of Research Europe and Head of Plasma Protein Research, CSL Behring. “We have also expanded our relationship with PreviPharma as their expertise is a natural complement to our plasma expertise. We are looking forward to growing our existing relationship and initiating new, high-value developments through this partnership.”

“We are excited to deepen our relationship with CSL Behring. With this agreement, CSL Behring and PreviPharma will continue our successful collaboration by adding new initiatives to develop novel plasma drug candidates for patients with unmet medical need. We are pleased that our Medical Innovation Platform and experienced scientific team have been selected to serve as a provider of innovative plasma protein research and patient data.” says Marc Mazur, CEO PreviPharma.

PreviPharma focuses on the therapeutic potential of plasma proteins used in novel therapeutic areas in addition to genetic disorder substitution therapies. The plasma protein market, including recombinant proteins, has grown to more than $20 billion of annual sales. However, only around 10 out of approximately 2500 proteins available in plasma have been developed for therapeutic use. Significant potential for new drug development opportunities derived from plasma remains untapped.

Other highly valuable and innovative Medical Innovation Platform (MIP) candidates with novel indications using plasma proteins are currently in development by PreviPharma. These candidates fall into various therapeutic areas such as hematology, infectious disease, gastrointestinal indications, neurology, and inflammation. PreviPharma is constantly improving its data generation capabilities for its proprietary MIP candidates to become exceptional new drug candidates.

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company’s products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), is headquartered in Melbourne, Australia, and the CSL group employs more than 27,000 people and delivers its life-saving therapies to people in more than 100 countries. For inspiring stories about the promise of biotechnology, visit Vita (CSLBehring.com/vita) and follow us on Twitter.com/CSLBehring.

Scientists from all around the world are working intensely on innovative treatments for the lung disease Covid-19. Mannheim is a centre of German medical technology and the company PreviPharma is working on very promising approaches in the foundation and competence centre CUBEX41. […]

Marc Mazur, CEO of PreviPharma:„ In order to save lives and relieve the burden on the healthcare system, we and our partners want to offer solutions for patients in urgent need as quickly as possible.“

read the full article (German language)

As PreviPharma stands forefront in addressing innovative drugs for the patient with unmet medical need, it has initiated a new program to combat globally occurring, life threatening conditions i.e Antimicrobial Resistance (AMR). Assumingly, about 700 000 deaths worldwide are caused each year by AMR. If current resistance rates increase by 40%, up to 9.5 million people may die each year. To combat such a deadly situation, PreviPharma initiated a new collaboration with Prof. Dr. Thomas Miethke of UMM.

Prof. Dr. Thomas Miethke is Head of Medical Microbiology and Hygiene, University Medicine Mannheim, Mannheim (UMM). He has a longstanding track record in the field of microbiology and especially antimicrobial resistance domain. His contributions are self-evidenced from numerous publications, mentorships, and awards to name a few.

‘’I am very much excited utilizing PreviPharma’s Medical Innovation Platform (MIP) and its therapeutic candidates on the road down to develop new treatment approaches for AMR. PreviPharma’s MIP program is a convincing approach in addressing unmet medical need and bears an impressive opportunity on finding new paths combating AMR. Therefore, we are very happy to collaborate with PreviPharma Consulting GmbH and are looking forward in bringing a fruitful outcome from this collaboration’’ said Prof.Thomas Miethke,UMM

Marc Mazur, CEO, PreviPharma Consulting GmbH added, “PreviPharma has significant expertise and strongly believes in working together for the development of novel, highly innovative drugs for severe diseases. Our MIP program is uniquely designed to combine potentials of academic and industrial partners to overcome unmet medical needs. We are highly optimistic that with a combination of Prof. Miethke experience and expertise and PreviPharma’s vision, we will be able to combat AMR in the future.”

PreviPharma today announces the start of a research collaboration with global biotherapeutics leader CSL Behring to develop a novel plasma protein-based drug for severely ill patients suffering from diseases with unmet medical needs. The program is based on PreviPharma’s Medical Innovation Platform (MIP) used for discovery, prototyping, and implementation of novel drug candidates. Under the terms of this agreement, PreviPharma will receive an upfront payment, with future milestone payments and royalties due upon program advancements. CSL Behring will retain full commercialization rights.

“As a company driven by its promise to patients, we are excited about our collaboration with PreviPharma, which seeks to identify a new and much needed option for the treatment of diseases with high unmet medical need,” says Dr Andrew Nash, Senior VP of Research, CSL Behring. “We have outsourced these early stage research and process development activities to PreviPharma, as their expertise is a natural complement to our program. Our ultimate goal is to discover new medical advancements, and to achieve a more rapid and focused progression of the project into development.”

“We are excited to support CSL Behring’s research activities with our Medical Innovation Platform approach. This cooperation will enable us to boost the recent R&D activities for this program to improve patients’ lives. PreviPharma already has a long-standing track record of successful collaboration with CSL Behring, which will now be supplemented by this new drug development cooperation,” says Marc Mazur, CEO PreviPharma.

PreviPharma focuses on the therapeutic potential of plasma proteins used in novel therapeutic areas in addition to genetic disorder substitution therapies. Plasma protein market including recombinant proteins has grown to more than $ 20 billion of annual sales. However, only around 10 out of approximately 2500 plasma proteins are presently available for therapeutic use. Significant potential for new drugs based on the so far unused proteins is left untapped.

Other highly valuable and innovative MIP candidates with novel indications using plasma proteins are currently in development by PreviPharma. These candidates fall into various therapeutic areas such as hematology, infectious disease, gastrointestinal indications, neurology, and inflammation. PreviPharma is constantly improving its data generation for its proprietary MIP candidates to become exceptional new drug candidates.

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, CSL Behring develops and delivers innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company’s products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn. CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 25,000 people, and delivers its life-saving therapies to people in more than 60 countries.

The need for innovative plasma-based therapies and a more efficient use of plasma donations is permanently increasing. The Innovation Hub is a result of PreviPharma’s Medical Innovation Platform on the road to becoming a leading research platform matching the highest demands for treatment of diseases with unmet clinical need.

‘We are delighted to further expand our MIP (Medical Innovation Platform) activities developing novel drugs to improve and save lives of patients with unmet medical need. PreviPharma’s choice of the UMM campus for this new facility reflects our approach of bringing together experts from medical, scientific, and commercial disciplines offering an excellent infrastructure and collaborative environment’, said Marc Mazur (CEO, PreviPharma).

PreviPharma’s new building in the middle of UMM campus, henceforth called Innovation Hub will add further capacity of 220 sqm to accommodate approximately up to 30 scientists and project related managers. In addition, it provides infrastructure such as meeting rooms with tele/video-conference opportunities, library facility, and a spacious lounge area to welcome our guests.

The existing PreviPharma premises in CUBEX 41 will now be fully dedicated for laboratory work, enabling the development of new processes and optimized analytics for a better, more efficient use of human plasma.

For more information please also visit https://previpharma.com/or contact us at info@previpharma.com.

PreviPharma attended Plasma Product Biotechnology Meeting 2019

June, 2019

This year’s Plasma Product Biotechnology Meeting, which had its twentieth anniversary was held in Sicily, Italy. It is one of the international key forums regarding the plasma fractionation industry and all of its aspects including manufacturing, clinical developments and technologic innovations.

PreviPharma aspires to participate in and shape the future of the plasma fraction industry by engaging in many cooperation’s with both, companies and academia. One of these cooperation’s with the University of Applied sciences in Bremerhaven concluded in an innovative and unique, analytical HPLC-MS/MS method, which PreviPharma presented as a poster during the conference.

PreviPharma plans to cooperate with legal authorities to implement this method as new standard in quality control of coagulation factor preparates.

Marc Mazur (left) and Dr. Stephan Kiessig (right) at the poster session.

The principle of the method comprises the measurement of indicative peptides to quantify and determine the quality of enzyme. The enzymes are denatured and digested by two proteases to generate comparable peptides. Coagulation factors that are already activated result in slightly different peptides due to the formation of an activation peptide or just an additional cleaving site. Those indicative peptides are then measured by LC-MS/MS analysis.

The proteins can therefore not only be quantified, it can also be differentiated between their states of activation due to the indicative peptides.

PreviPharma and Ludwig-Maximilians-University (LMU) Munich collaborate to share common platform to address unmet medical needs

May, 2019

PreviPharma has started an initiative to integrate partners from both academic and industrial set up, whose expertise, innovations and technologies offer significant advantages to address unmet medical needs. In this aspect, PreviPharma initiated a successful collaboration with Prof. Hans-Joachim Anders of University Hospital of the Ludwig-Maximilians-University, Munich.

Prof. Hans-Joachim Anders is the group leader, head of the Department of Nephrology and the Kidney Research Institute. He also contributed to numerous EU network programs as a work package leader including to REDDSTAR, NEPHSTROM, RELENT, Volkswagen Stiftung to name a few.

“We are very happy to collaborate with PreviPharma Consulting GmbH. The Medical Innovation Platform program has a clear vision of bringing academic and industry partners together and approaching unmet medical needs in a result-oriented way. PreviPharma’s deep experience with plasma proteins and good relationships into the pharma industry is unique and critical to identifing solutions for medical problems.”

Prof. Hans-Joachim Anders, LMU München

“PreviPharma’s MIP program is geared towards integrating research partners to jointly develop approaches to address and overcome unmet medical needs. We are highly optimistic that the combination of PreviPharma’s vision and Prof. Anders experience and expertise will bring changes in patient care and provide solutions of the medical needs.”

Dr. Satish Deverapu, Director Partner Management, PreviPharma

Marc Mazur (CEO), Satish Kumar Devarapu (Director Partner Management) and Maurice Mandago (Senior Scientist) took the opportunity to learn about current applications of AI in the pharma sector and network with partner companies.

PreviPharma’s Medical Innovation Platform offers ways to identify new possibilities of using plasma proteins. Benefits for pharma companies include reduced time from idea to clinical trial and increased innovation success rates. PreviPharma already uses Business Intelligence as pre-stage of an AI-approach for the discovery of new uses of plasma proteins.

PreviPharma’s MIP-Discovery Approach

PreviPharma assesses new indications and “hidden gems” by using a feedback loop of data analysis and evaluation. The loop begins with the collection of literature from public domain, expert opinions, patient and market data and other sources of data. These data packages are matched and evaluated on the first level by AI to identify new deficiencies. Then, newly identified hits are evaluated by PreviPharma’s team of experts and key-opinion-leaders (KoL).

For more information visit: https://previpharma.com/medical-innovation-platform/,

https://www.technologiepark-heidelberg.de/en/, and

https://www.technologiepark-heidelberg.de/events/zukunfts-bar-kuenstliche-intelligenz/

or contact us at info@previpharma.com

PreviPharma initiates Preferred Partner Program with CoaChrom

March, 2019

PreviPharma has started an initiative to nominate important partners, whose innovations and technologies offer significant advantages to evolve and improve plasma fractionation. PreviPharma’s first pick goes to CoaChrom Diagnostica. CoaChrom offers a large and steadily growing portfolio of analytical methods focused on coagulation and fibrinolysis. CoaChrom’s test kits and reagents are used for early diagnostics in protein discovery projects in PreviPharma’s Medical Innovation Platform (MIP) and for protein process developments in PreviPharma’s Technology Innovation Platform (TIP).

“We have found a very competent, innovative and reliable partner in CoaChrom. Their assays can be performed easily by our scientists, service quality is excellent and were already successfully transferred to customers around the world.”

Marc Mazur, CEO PreviPharma

“We are pleased to work with innovative research and service companies such as PreviPharma. Within in a few years, PreviPharma’s MIP has grown into a complete set of services that we can support with our assay methods. We look forward to working with the PreviPharma team in many innovative projects.”

Bernhard Kolmer, CEO CoaChrom

Furthermore, the innovative Thrombodynamics-4D system of CoaChroms partner company HemaCore allows a new level of understanding of coagulation and has been used by PreviPharma to evaluate the efficacy of newly-developed coagulometric and fibrinolytic drugs.

To learn more about PreviPharma’s Medical and Technology Innovation Platforms and how we can assist you in designing or optimizing your desired fractionation process using state-of-the-art analytics, provided by CoaChrom next-gen technology, please visit: http://www.previpharma.com/.

Visit also http://www.coachrom.com/ and https://www.thrombodynamics.com/ for more information.